Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab vs Adalimumab and Placebo in Active Ankylosing Spondylitis
2011-002325-22Phase 3Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ixekizumab in ankylosing spondylitis (AS) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: ASAS20 response at week 16. Started Jun 2013; status: terminated.
02
Drugs
ixekizumab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on 2011-002325-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-002325-22.